Fibrinogen Degradation Products and D-Dimers in Patients with Breast Carcinoma

Background: Many patients with cancer are complicated by disseminated intravascular coagulation. This study was aimed to determine the level of Fibrinogen Degradation Products and D-Dimers at various stages in patients suffering from breast carcinoma. Material and methods: This was a cross-section...

Full description

Bibliographic Details
Main Authors: Malik Zeb Khan, Muhammad Shoaib Khan, Fazle Raziq, Aziz Marjan Khattak
Format: Article
Language:English
Published: Gomal Medical College, D.I.Khan, Pakistan 2007-06-01
Series:Gomal Journal of Medical Sciences
Online Access:http://gjms.com.pk/ojs24/index.php/gjms/article/view/95
id doaj-055da85f13554662bd2cd83dfd49a385
record_format Article
spelling doaj-055da85f13554662bd2cd83dfd49a3852020-11-25T01:43:47ZengGomal Medical College, D.I.Khan, PakistanGomal Journal of Medical Sciences1819-79731997-20672007-06-015195Fibrinogen Degradation Products and D-Dimers in Patients with Breast CarcinomaMalik Zeb KhanMuhammad Shoaib KhanFazle RaziqAziz Marjan KhattakBackground: Many patients with cancer are complicated by disseminated intravascular coagulation. This study was aimed to determine the level of Fibrinogen Degradation Products and D-Dimers at various stages in patients suffering from breast carcinoma. Material and methods: This was a cross-sectional study conducted in the Department of Pathology, Postgraduate Medical Institute, Lahore, Pakistan, from June 2003 to June 2004. Sampling method was by convenience. Two groups were taken; Group-1 including 50 patients with breast carcinoma and Group-2 comprising of 25 healthy controls. Fibrinogen Degradation Products and D-Dimer levels were estimated in the blood and the results compared. Results: Out of 50 patients, 28 (56%) had Fibrinogen Degradation Products >40 μg/ml; 13 (26%) in stageIII and 15 (30%) in stage-IV. 15 (30%) patients had levels between 5-40μg/ml; 8 (16%) in stage-II and 7 (14%) in stage-III. Only 7 (14%) had levelshttp://gjms.com.pk/ojs24/index.php/gjms/article/view/95
collection DOAJ
language English
format Article
sources DOAJ
author Malik Zeb Khan
Muhammad Shoaib Khan
Fazle Raziq
Aziz Marjan Khattak
spellingShingle Malik Zeb Khan
Muhammad Shoaib Khan
Fazle Raziq
Aziz Marjan Khattak
Fibrinogen Degradation Products and D-Dimers in Patients with Breast Carcinoma
Gomal Journal of Medical Sciences
author_facet Malik Zeb Khan
Muhammad Shoaib Khan
Fazle Raziq
Aziz Marjan Khattak
author_sort Malik Zeb Khan
title Fibrinogen Degradation Products and D-Dimers in Patients with Breast Carcinoma
title_short Fibrinogen Degradation Products and D-Dimers in Patients with Breast Carcinoma
title_full Fibrinogen Degradation Products and D-Dimers in Patients with Breast Carcinoma
title_fullStr Fibrinogen Degradation Products and D-Dimers in Patients with Breast Carcinoma
title_full_unstemmed Fibrinogen Degradation Products and D-Dimers in Patients with Breast Carcinoma
title_sort fibrinogen degradation products and d-dimers in patients with breast carcinoma
publisher Gomal Medical College, D.I.Khan, Pakistan
series Gomal Journal of Medical Sciences
issn 1819-7973
1997-2067
publishDate 2007-06-01
description Background: Many patients with cancer are complicated by disseminated intravascular coagulation. This study was aimed to determine the level of Fibrinogen Degradation Products and D-Dimers at various stages in patients suffering from breast carcinoma. Material and methods: This was a cross-sectional study conducted in the Department of Pathology, Postgraduate Medical Institute, Lahore, Pakistan, from June 2003 to June 2004. Sampling method was by convenience. Two groups were taken; Group-1 including 50 patients with breast carcinoma and Group-2 comprising of 25 healthy controls. Fibrinogen Degradation Products and D-Dimer levels were estimated in the blood and the results compared. Results: Out of 50 patients, 28 (56%) had Fibrinogen Degradation Products >40 μg/ml; 13 (26%) in stageIII and 15 (30%) in stage-IV. 15 (30%) patients had levels between 5-40μg/ml; 8 (16%) in stage-II and 7 (14%) in stage-III. Only 7 (14%) had levels
url http://gjms.com.pk/ojs24/index.php/gjms/article/view/95
work_keys_str_mv AT malikzebkhan fibrinogendegradationproductsandddimersinpatientswithbreastcarcinoma
AT muhammadshoaibkhan fibrinogendegradationproductsandddimersinpatientswithbreastcarcinoma
AT fazleraziq fibrinogendegradationproductsandddimersinpatientswithbreastcarcinoma
AT azizmarjankhattak fibrinogendegradationproductsandddimersinpatientswithbreastcarcinoma
_version_ 1725031484397453312